Canada: New Canadian Regulations for Natural Health Products

Last Updated: March 31 2004

By Charles Boulakia and Cynthia Tape

Published in FDLI Update, March/April 2004.

As of January 1, 2004, natural health products (NHPs) in Canada are subject to new sale, manufacturing, packaging, labeling, storage, importation, and distribution requirements.

Under the new Natural Health Products Regulations,1 NHPs are materials, extracts, or isolates of plants, algae, bacteria, fungus, or animals; natural or synthetic amino acids, essential fatty acids, or certain vitamins; minerals; probiotics; homeopathic medicines; or traditional medicines that are manufactured, sold, or represented for use in the diagnosis, treatment, mitigation, or prevention of a disease, disorder, or abnormal physical state or its symptoms, or for restoring, modifying, or correcting organic functions in humans.

Some products are not classi.ed as NHPs, including allergenic substances used for the treatment or diagnosis of allergic or immunological diseases; blood and blood derivatives; drugs obtained by recombinant DNA procedures; drugs other than antibiotics prepared from micro-organisms; immunizing agents; insulin; interferon; monoclonal antibodies; substances regulated under the Tobacco Act;2 substances regulated by the Controlled Drugs and Substances Act;3 substances that are administered by puncturing the dermis; antibiotics prepared from algae, bacterium, or fungi, or synthetic duplicates of such an antibiotic; and prescription drugs.

Product Licensing and Drug Identification

Effective January 1, 2004, no person is permitted to sell an NHP in Canada unless a product license is issued. A person seeking to market an NHP must .rst apply for, and obtain, an NHP license or, in the case of homeopathic medicines, a Drug Identi.cation Number-Homeopathic Medicine (DIN-HM). The application must be submitted to the newly formed Natural Health Products Directorate, and must include information such as the following:

  • the proper name and common name of each medicinal ingredient;
  • the quantity of each medicinal ingredient per dosage unit;
  • the potency of each medicinal ingredient if a representation relating to its potency is shown on the label;
  • a description of the source material of each medicinal ingredient, and a statement indicating whether it is synthetically manufactured;
  • a list of nonmedicinal ingredients and the purpose of each;
  • the proposed brand name of the NHP;
  • the recommended conditions of use for the NHP;
  • information supporting the safety and ef.cacy of the NHP when used in accordance with the recommended conditions of use;
  • the text of each label proposed to be used in conjunction with the product;
  • a copy of the speci.cations with which the product will comply; and
  • an attestation that the product is manufactured, packaged, labeled, distributed, stored, and imported (if applicable) in accordance with good manufacturing practices contained in the NHP Regulations.

The NHP Directorate may request additional information or samples of the product if the information submitted is insuf.cient to enable it to determine whether the license should be issued.

The holder of the NHP license has a continuing obligation to document adverse reactions with respect to the NHP, reactions in an annual summary report, and to report to the Minister of Health all serious adverse reactions in Canada or serious unexpected adverse reactions anywhere in the world. The holder of the NHP license has an obligation to maintain records related to the ingredients contained in each lot or batch of the NHP and suf.cient information to enable the recall of every lot or batch made available for sale.

Site License and Good Manufacturing Practices

Those who manufacture, package, label, or import an NHP must have a site license. Site licenses may be obtained by submitting an application to the NHP Directorate (forms are available on the Directorate’s website at www.hc-sc.gc. ca/hpfb-dgpsa/nhpd-dpsn/forms_e.html). The licenses are valid for one year from the date of issue and can be renewed for periods of up to three years.

Those who manufacture, package, label, import, distribute, or store an NHP must do so in accordance with good manufacturing practices that are contained in the NHP Regulations. These practices include compliance with the speci.cations submitted in an application for an NHP license, as well as requirements related to recordkeeping, recall reporting, equipment use, personnel, premises, sanitation programs, quality assurance, stability, operations, sterile products, ophthalmic use products, and lot or batch samples.

Clinical Trials

The NHP Regulations set out detailed requirements for the performance of clinical trials on NHPs.

Labeling and Packaging

Under the NHP Regulations, the label of the NHP must— subject to small-package exemptions—include the following:

  • the brand name for the NHP;
  • the product’s NHP license number, lot number, and expiry date;
  • the recommended use or purpose of the NHP;
  • the recommended route of administration, dose, dosage form, and duration of use of the NHP;
  • the risk information relating to the NHP, including any cautions, warnings, contra-indications, or known adverse reactions associated with its use;
  • the common name of each medicinal ingredient, and its proper name if the proper name is not the chemical name of the ingredient;
  • the name and address of the product license holder and importer (where applicable);
  • the quantity and authorized potency (if applicable) per dosage unit of the medicinal ingredients;
  • the net amount of product in the container;
  • storage conditions, if any are recommended;
  • a description of the source material of each medicinal ingredient;
  • the word "sterile" (if applicable);
  • a list of all nonmedicinal ingredients; and
  • the quantity of mercury contained within the product (if applicable).

Much of this information is required to be in both English and French, and on both the inner and outer labels of the NHP. In addition, NHPs will need to have security packaging.

Transition Period

The NHP Regulations came into force January 1, 2004. There is no transition period for new products that are NHPs, so these products must comply with the regulations as of that date.

There is a six-year transition period (i.e., until December 31, 2009) for products that currently have DINs.

There is a two-year transition period (i.e., until December 31, 2005) for the good manufacturing practices and site license requirements of the regulations (but not for the licensing requirements) for products that have been manufactured, packaged, labeled, or imported before January 1, 2004.

There are additional transition periods for products that were authorized for clinical trial before January 1, 2004.

Although the NHP Regulations indicate that all products already on the market will require an NHP license on January 1, 2004, the NHP Directorate has indicated that it will stagger enforcement over four years (i.e., through January 1, 2008), depending on the type of product. For example, a probiotic that is on the market before January 1, 2004; that is not deemed a health risk;4 that is not on the Therapeutic Product NHP Directorate’s New Drug List; and that contains no extracts, isolates, amino acids, or essential fatty acids will not be subject to a compliance action until June 2005. It remains to be seen, however, how this phased-in compliance and enforcement will be dealt with when consumer or trade complaints are made. The prudent course is to apply for and secure the necessary licenses now.

Torys LLP (www.torys.com) is an international business law firm with more than 330 lawyers in New York and Toronto.

1 Natural Health Products Regulations, S.O.R./2003-196.

2 Tobacco Act, S.C. 1997, c. 1.

3 Controlled Drugs and Substances Act, S.C. 96, c. 19.

4 This includes that it is not a Schedule A or F drug; not a sterile product; not a prohibited substance; not used by children, pregnant, or breast-feeding women; and not a health hazard.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
In association with
Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions